| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 358.25 | 21879 |
| Intrinsic value (DCF) | 17.99 | 1004 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.